Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S. Yamamoto N, et al. Among authors: nakayama t. Breast Cancer Res Treat. 2012 Feb;132(1):165-73. doi: 10.1007/s10549-011-1575-2. Epub 2011 May 19. Breast Cancer Res Treat. 2012. PMID: 21594664
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N, Taguchi T, Nakayama T, Shiba E, Watatani M, Kurebayashi J, Takatsuka Y, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Masuda N, et al. Among authors: nakayama t. Cancer Chemother Pharmacol. 2008 May;61(6):989-95. doi: 10.1007/s00280-007-0555-z. Epub 2007 Jul 20. Cancer Chemother Pharmacol. 2008. PMID: 17641893 Clinical Trial.
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group. Taguchi T, et al. Among authors: nakayama t. Chemotherapy. 2010;56(2):166-70. doi: 10.1159/000313531. Epub 2010 Apr 21. Chemotherapy. 2010. PMID: 20407245 Clinical Trial.
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population.
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group. Toi M, et al. Among authors: nakayama t. Cancer. 2010 Jul 1;116(13):3112-8. doi: 10.1002/cncr.25206. Cancer. 2010. PMID: 20564629 Free article.
Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)].
Taguchi T, Masuda N, Nakayama T, Motomura K, Tsukamoto F, Shimazu K, Nomura T, Morimoto T, Yamamoto H, Wakita K, Nakano Y, Yoneda K, Inaji H, Takatsuka Y, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Taguchi T, et al. Among authors: nakayama t. Oncology. 2010;78(5-6):302-8. doi: 10.1159/000318169. Epub 2010 Jul 2. Oncology. 2010. PMID: 20606491 Clinical Trial.
5,197 results